M. Picard

发表

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

J. Milanowski, C. Gridelli, D. Atanackovic, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

R. Stupp, M. Weller, T. Gorlia, 2016, Oncotarget.

Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM)

R. Stupp, M. Weller, M. Hegi, 2007 .

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

R. Stupp, M. Weller, T. Gorlia, 2018, Journal of Neuro-Oncology.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Alessia Pica, Bart Neyns, Michael Weller, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does cilengitide deserve another chance?-Authors' reply.

R. Stupp, M. Weller, M. Picard, 2014, The Lancet. Oncology.

Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC).

R. Stupp, M. Weller, M. Hegi, 2010 .

Integrins as therapeutic targets.

S. Goodman, Simon L Goodman, Martin Picard, 2012, Trends in pharmacological sciences.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

K. Aldape, D. Grujičić, R. Stupp, 2014, The Lancet. Oncology.

Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression

R. Stupp, M. Weller, G. Nikkhah, 2014, Journal of Neuro-Oncology.

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

T. Mikkelsen, D. Grujičić, D. Nam, 2015, Neuro-oncology.

Targeting integrins in malignant glioma

T. Mikkelsen, R. Stupp, M. Weller, 2010, Targeted Oncology.

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.

T. Mikkelsen, T. Cloughesy, D. Schiff, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009

T. Mikkelsen, D. Schiff, J. Raizer, 2007 .

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.

D. Grujičić, M. J. van den Bent, M. Weller, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study.

David Schiff, T. Mikkelsen, D. Schiff, 2010 .

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.

T. Mikkelsen, T. Cloughesy, D. Schiff, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.

R. Stupp, M. Weller, M. Taphoorn, 2013 .

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

R. Stupp, M. Weller, T. Gorlia, 2018, Journal of Neuro-Oncology.